Literature DB >> 22985566

[CA916798 gene participates in cisplatin resistance of human lung adenocarcinoma A549 cells through PI3K/AKT/mTOR pathway].

Zhanzhong Qi1, Yuliang Wang, Xiangdong Zhou.   

Abstract

OBJECTIVE: To observe the changes of CA916798 gene expression in human lung adenocarcinoma cell A549 and the multidrug-resistant cell line A549/CDDP after blocking the PI3K/AKT/mTOR pathway.
METHODS: Human lung adenocarcinoma cell lines A549 and A549/CDDP were treated with rapamycin and LY294002, and the cell growth changes in response to subsequent cisplatin treatment was observed; RT-PCR was performed to detect CA916798 mRNA expression in the treated cells.
RESULTS: Blocking PI3K/AKT/mTOR pathway with rapamycin and LY294002 significantly reduced drug resistance of both A549 and A549/CDDP cells to cisplatin and obviously decreased the expression of CA916798 gene mRNA (P<0.05).
CONCLUSION: CA9167981 gene is located downstream of the PI3K/AKT/mTOR pathway, which might be one of the mechanisms of CA916798 to cause cisplatin resistance in the tumor cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22985566

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  4 in total

1.  Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.

Authors:  Xuemei Yang; Chunlan Tang; Hu Luo; Haijing Wang; Xiangdong Zhou
Journal:  Oncotarget       Date:  2017-04-04

2.  [Effect of PI3K/AKT pathway on cisplatin resistance in non-small cell lung cancer].

Authors:  Yu Zhang; Hongling Lu; Gang Xu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-08-20

3.  CA916798 gene expression is associated with multidrug resistance and predicts progression-free survival in patients with lung cancer.

Authors:  Hailing Duan; Zaixing Yang; Lan Liang; Xiangdong Zhou
Journal:  Oncol Lett       Date:  2019-06-04       Impact factor: 2.967

Review 4.  Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and Limitations.

Authors:  Shuta Ohara; Kenichi Suda; Tetsuya Mitsudomi
Journal:  Cells       Date:  2021-02-09       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.